已经显示在肝脏受损的时候，细胞外循环血液中的肝脏特异性microRNA -122 （miR-122）的水平会上升。然而，对于血清miR-122水平在抗病毒治疗中是否会变化以及它是否能反映治疗成功还是未知的。在这里，我们调查了慢性丙型肝炎病毒（HCV）感染基因1型患者在应用聚乙二醇干扰素和利巴韦林抗病毒治疗过程中血清miR-122的水平。因此，60名慢性丙型肝炎病毒基因1型感染患者在抗病毒治疗基线水平、4周、12周、24周、治疗结束及随访时期的血清反映了对治疗的持续病毒学应答、无应答及复发，我们利用实时定量逆转录聚合酶链式反应的方法对这些血清中的miR-122含量进行了回顾性分析。miR-122的变化水平与HCV-RNA及标准肝参数相关联。我们发现，血清中的miR -122和HCV-RNA水平在基线时没有关系，而开始治疗时HCV-RNA下降在三个不同的患者群体均与血清中miR-122降低密切相关。此外，血清中的miR -122水平也与丙氨酸氨基转移酶（ALT）相关，是持续性肝脏损害的一个标志。在持续病毒学应答（SVR）随访时期，血清中的miR-122的水平仍然较低，但比无应答及复发组要高。与此相反，广泛表达的miR -16的血清浓度在治疗过程中并没有改变。我们得出结论，血清中miR-122很好地体现了慢性丙型肝炎病毒感染患者用干扰素/利巴韦林联合抗病毒治疗的成功。
The levels of the liver-specific microRNA-122 (miR-122) circulating extracellularly in the blood have been shown to be increased upon liver damage. However, it is unknown if the levels of serum miR-122 are altered during antiviral therapy and reflect the therapeutic success. Here, we investigated miR-122 serum levels in patients with chronic hepatitis C virus (HCV) genotype 1 infection during antiviral therapy with pegylated interferon and ribavirin. Therefore, sera from 60 patients with chronic HCV infection genotype 1 showing sustained virological response (SVR), non-response or relapse to therapy obtained at baseline, 4, 12, 24 weeks, end of treatment and follow-up were analysed retrospectively for miR-122 content by quantitative real-time reverse transcription PCR. The time courses of miR-122 were correlated with HCV RNA as well as standard liver parameters. We found that while there was no relation between serum miR-122 and HCV RNA levels at baseline, the decline in HCV RNA upon beginning of thetherapy closely correlated with the reduction of serum miR-122 in the three different patient groups. Moreover, the serum miR-122 level correlated well with alanine aminotransaminase, a marker of ongoing liver damage. At follow-up serum miR-122 levels remained low in SVR, but increased to baseline levels in patients not responding or showing relapse to therapy. In contrast, the serum concentration of the ubiquitously expressed miR-16 did not change during therapy. We conclude that the serum level of miR-122 well reflects the success of interferon/ribavirin therapy in patients withchronic HCV infection.
吉林大学第一医院肝病科 祁凌霞 摘译
本文首次发表于[J Viral Hepat. 2013 Aug;20(8):530-5]
本文首次发表于[J Viral Hepat. 2013 Aug;20(8):530-5]
Serum microRNA-122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy.
AbstractThe levels of the liver-specific microRNA-122 (miR-122) circulating extracellularly in the blood have been shown to be increased upon liver damage. However, it is unknown if the levels of serum miR-122 are altered during antiviral therapy and reflect the therapeutic success. Here, we investigated miR-122 serum levels in patients with chronic hepatitis C virus (HCV) genotype 1 infection during antiviral therapy with pegylated interferon and ribavirin. Therefore, sera from 60 patients with chronic HCV infection genotype 1 showing sustained virological response (SVR), non-response or relapse to therapy obtained at baseline, 4, 12, 24 weeks, end of treatment and follow-up were analysed retrospectively for miR-122 content by quantitative real-time reverse transcription PCR. The time courses of miR-122 were correlated with HCV RNA as well as standard liver parameters. We found that while there was no relation between serum miR-122 and HCV RNA levels at baseline, the decline in HCV RNA upon beginning of thetherapy closely correlated with the reduction of serum miR-122 in the three different patient groups. Moreover, the serum miR-122 level correlated well with alanine aminotransaminase, a marker of ongoing liver damage. At follow-up serum miR-122 levels remained low in SVR, but increased to baseline levels in patients not responding or showing relapse to therapy. In contrast, the serum concentration of the ubiquitously expressed miR-16 did not change during therapy. We conclude that the serum level of miR-122 well reflects the success of interferon/ribavirin therapy in patients withchronic HCV infection.
